Get the Stockscreener App
0.4111
2.12%
-0.0089
After Hours:
.45
0.0389
+9.46%
Shuttle Pharmaceuticals Holdings Inc stock is traded at $0.4111, with a volume of 88,737.
It is down -2.12% in the last 24 hours and down -35.60% over the past month.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
See More
Previous Close:
$0.42
Open:
$0.42
24h Volume:
88,737
Relative Volume:
0.64
Market Cap:
$2.02M
Revenue:
-
Net Income/Loss:
$-7.35M
P/E Ratio:
-0.8937
EPS:
-0.46
Net Cash Flow:
$-5.48M
1W Performance:
-5.58%
1M Performance:
-35.60%
6M Performance:
-74.62%
1Y Performance:
-5.69%
1-Day Range:
$0.391
$0.4323
1-Week Range:
$0.331
$0.485
52-Week Range:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Name
Shuttle Pharmaceuticals Holdings Inc
Sector
Phone
(240) 403-4212
Address
401 PROFESSIONAL DRIVE, GAITHERSBURG
Compare SHPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.4111 | 2.02M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
SHPH stock touches 52-week low at $0.34 amid market challenges By Investing.com - Investing.com South Africa
SHPH stock touches 52-week low at $0.34 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
SHPHSHUTTLE PHARMACTCLS HLDGS INC Latest Stock News & Market Updates - StockTitan
Shuttle Pharma Announces Closing Of $5.75 Million Underwritten Offering -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Shuttle Pharma Secures $5.2M in Public Offering - TipRanks
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering - GlobeNewswire
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering - Benzinga
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - StockTitan
Shuttle Pharma appoints new interim co-CEO By Investing.com - Investing.com Australia
This Md. biotech wants to get a cancer treatment to patients. It just tapped an industry outsider as co-CEO. - The Business Journals
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Shuttle Pharma announces $5.75 million stock offering By Investing.com - Investing.com South Africa
Shuttle Pharma announces $5.75 million stock offering - Investing.com
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering -March 12, 2025 at 09:25 am EDT - Marketscreener.com
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering - GlobeNewswire
Shuttle Pharma Secures Critical $5.75M Funding for Revolutionary Cancer Radiation Therapy - StockTitan
4 Artificial Intelligence (AI) Stocks Worth Buying in the Tech Sell-Off - The Globe and Mail
Lucid Group (LCID) Prepares to Sink Into Penny Stock Territory - The Globe and Mail
1 Large-Cap Stock with Solid Fundamentals and 2 to Avoid - The Globe and Mail
Shuttle Pharma appoints new interim co-CEO - Investing.com
Shuttle Pharma Appoints Christopher Cooper as Interim Co-CEO - citybiz
Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO - TipRanks
Shuttle Pharma Announces Appointment Of Christopher Cooper As Interim Co-CEO To Enhance Business Activities - Marketscreener.com
Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO - TipRanks
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities - GlobeNewswire
Shuttle Pharma Strengthens Leadership: New Co-CEO to Accelerate Growth While Phase 2 Trial Advances - StockTitan
2 Reasons to Watch GE and 1 to Stay Cautious - The Globe and Mail
SHPH stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com Australia
SHPH stock touches 52-week low at $0.5 amid sharp annual decline By Investing.com - Investing.com South Africa
Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected - The Globe and Mail
Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock -March 05, 2025 at 07:42 am EST - Marketscreener.com
Amendment: SEC Form S-1/A filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Enters Revolving Loan Agreement - TipRanks
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement -February 28, 2025 at 05:26 pm EST - Marketscreener.com
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement - TradingView
3 Reasons to Sell RH and 1 Stock to Buy Instead - The Globe and Mail
SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Amends Agreement with Alto Fund By Investing.com - Investing.com Australia
Shuttle Pharmaceuticals Amends Agreement with Alto Fund - Investing.com
SHPH stock touches 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
SHPH stock touches 52-week low at $0.57 amid market challenges - Investing.com
Shuttle Pharma advances glioblastoma trial, expands diagnostics - Investing.com India
Shuttle Pharma advances glioblastoma trial, expands diagnostics By Investing.com - Investing.com South Africa
Shuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual Update - Nasdaq
Shuttle Pharma Provides Corporate Update and Reports 2024 Results - GlobeNewswire
Can Shuttle Pharma's Glioblastoma Treatment Breakthrough Deliver Returns? CEO Bets $237K - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):